Novartis sees sales boost from key cancer drugs [Yahoo! Finance Canada]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Yahoo! Finance Canada
FRANKFURT (Reuters) -Swiss drugmaker Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as ?higher forecast peak sales for cancer drugs Kisqali and Scemblix offset losses from expiring patents. ? Shares of the company rose about 1% in early trade. They have gained 16% so far this year. Novartis has been ?on a $30-billion spending spree on acquisitions and licensing deals this year to bolster its pipeline ahead of patent expiries for its top-selling heart treatment Entresto and asthma drug Xolair. HIGHER PEAK SALES FORECASTS The company said it now expects peak sales for breast cancer drug Kisqali of at least $10 billion, versus a previous estimate of $8 billion. For leukaemia drug Scemblix, it expects peak sales of ?at least $4 billion, up from ?at least $3 billion. Jefferies analysts said there was "ample room" to raise targets further for the two drugs. In the first nine months of 2025, Kisqali and Scemblix made combined
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences, Inc. (RNA): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBXPR Newswire
- Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs [CNBC]CNBC
- Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44PR Newswire
- Avidity Biosciences (NASDAQ:RNA) had its "hold" rating reaffirmed by analysts at Cowen Inc.MarketBeat
RNA
Earnings
- 11/10/25 - Miss
RNA
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/24/25 - Form PREM14A
- 11/20/25 - Form DEFA14A
- RNA's page on the SEC website